Form 4: Crinetics Director Sells Shares via 10b5-1 Plan

Crinetics Pharmaceuticals Director Stephanie Okey sold 3,000 shares of common stock for $39.67 each, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Stephanie Okey, a Director at Crinetics Pharmaceuticals, Inc. (CRNX), reported a sale of common stock.
• The transaction involved the disposition of 3,000 shares of Crinetics Pharmaceuticals common stock.
• The shares were sold at a price of $39.67 per share.
• The total value of the transaction was $119,010 (3,000 shares * $39.67/share).
• The sale was executed on March 3, 2026.
• This sale was conducted automatically pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Okey on November 19, 2025.
• Following this transaction, Ms. Okey beneficially owns 13,300 shares of Crinetics Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged 10b5-1 plan, which typically carries a neutral sentiment as it's often for personal financial planning rather than a direct signal about company performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are common practice for corporate insiders to diversify their holdings or manage personal liquidity needs. Such pre-arranged sales are typically scheduled well in advance and are not necessarily indicative of management's immediate sentiment regarding the company's short-term prospects, distinguishing them from opportunistic, unscheduled sales.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, but given it's a planned transaction, it is unlikely to significantly impact shareholder confidence or the company's valuation.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Sale, Stephanie Okey, 10b5-1 Plan, Director Transaction, Biotechnology